Steve Kelly and the other panelists discuss their paper titled “Assessing the policy and access environment across European countries for SMA patients.”
For more information on this event, click here.
CRA's RADAR Insights: Factors impacting GKV rebates for orphan drugs in Germany - Part 1
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...